Literature DB >> 22968039

Engineering NGF receptors to bind Grb2 directly uncovers differences in signaling ability between Grb2- and ShcA-binding sites.

Shinichiro Oku1, Talitha van der Meulen, Jeremy Copp, Gary Glenn, Peter van der Geer.   

Abstract

Grb2 and ShcA are two phosphotyrosine-binding proteins that link receptor protein-tyrosine kinases to activation of the Ras-Erk pathway. While some receptors bind Grb2 directly, others bind ShcA, which provides a binding site for Grb2. In order to compare signal transduction through a Grb2-binding site with signal transduction through a ShcA-binding site, we replaced the ShcA-binding site in the NGF receptor with a Grb2-binding site. Our results show that the Grb2- and ShcA-binding sites have similar abilities to activate the Ras-Erk and PI 3-kinase-Akt pathways. In contrast, they displayed dramatic differences in their ability to activate DNA synthesis.
Copyright © 2012 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22968039     DOI: 10.1016/j.febslet.2012.08.021

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  3 in total

1.  Biphasic spatiotemporal regulation of GRB2 dynamics by p52SHC for transient RAS activation.

Authors:  Ryo Yoshizawa; Nobuhisa Umeki; Akihiro Yamamoto; Masayuki Murata; Yasushi Sako
Journal:  Biophys Physicobiol       Date:  2021-01-08

2.  Met receptor-induced Grb2 or Shc signals both promote transformation of intestinal epithelial cells, albeit they are required for distinct oncogenic functions.

Authors:  Véronique Pomerleau; Mélissa Landry; Jimmy Bernier; Pierre H Vachon; Caroline Saucier
Journal:  BMC Cancer       Date:  2014-04-04       Impact factor: 4.430

3.  p52Shc regulates the sustainability of ERK activation in a RAF-independent manner.

Authors:  Ryo Yoshizawa; Nobuhisa Umeki; Akihiro Yamamoto; Mariko Okada; Masayuki Murata; Yasushi Sako
Journal:  Mol Biol Cell       Date:  2021-07-14       Impact factor: 4.138

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.